Characteristics of hypertension in the black population.
D000328:Adult; D001741:Black or African American; D000804:Angiotensin II / Q000097:blood / Q000378:metabolism; D000818:Animals; D006332:Cardiomegaly / Q000209:etiology; D002561:Cerebrovascular Disorders / Q000209:etiology; D002752:Chlorthalidone / Q000627:therapeutic use; D003327:Coronary Disease / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D006145:Guanethidine / Q000627:therapeutic use; D006352:Heart Ventricles; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D008875:Middle Aged; D009519:New York City; D011817:Rabbits / Q000276:immunology; D011863:Radioimmunoassay; D012083:Renin / Q000097:blood; D012964:Sodium / Q000652:urine; D013148:Spironolactone / Q000627:therapeutic use
D000804:Angiotensin II; D006830:Hydralazine; D013148:Spironolactone; D008750:Methyldopa; D012964:Sodium; D012083:Renin; D002752:Chlorthalidone; D006145:Guanethidine